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Parkinson’s disease (PD) is a devastating neurological movement disorder. Since its first
discovery 200 years ago, genetic and environmental factors have been identified to
play a role in PD development and progression. Although genetic studies have been
the predominant driving force in PD research over the last few decades, currently
only a small fraction of PD cases can be directly linked to monogenic mutations. The
remaining cases have been attributed to other risk associated genes, environmental
exposures and gene–environment interactions, making PD a multifactorial disorder
with a complex etiology. However, enormous efforts from global research have yielded
significant insights into pathogenic mechanisms and potential therapeutic targets for
PD. This review will highlight mitochondrial dysfunction as a common pathway involved
in both genetic mutations and environmental toxicants linked to PD.
Keywords: Parkinson’s disease, mitochondrial dynamics, mitochondrial dysfunction, neurodegeneration,
neurotoxicity, environmental toxins, gene–environment interaction

INTRODUCTION
Parkinson’s disease (PD), characterized by degeneration of the nigrostriatal dopaminergic pathway,
is the second most prevalent neurodegenerative disorder after Alzheimer’s disease. Pathological
hallmarks of PD include the loss of dopaminergic neurons in the substantia nigra pars compacta
(SNpc) and the presence of cytoplasmic protein aggregates known as Lewy bodies in remaining
dopaminergic neurons (Przedborski, 2017). When degeneration in these neurons results in a
threshold reduction of approximately 80% of striatal dopamine, motor symptoms of PD such
as rigidity, resting tremor, bradykinesia and postural instability start to emerge (Dauer and
Przedborski, 2003). PD is a complex and multifactorial brain disorder. Approximately 30% of
the familial and 3–5% of sporadic PD cases are caused by monogenic mutations, while the
other remaining cases are classified as idiopathic and sporadic with unknown etiology (Klein
and Westenberger, 2012; Hernandez et al., 2016). Environmental factors and gene–environment
interactions have been implicated in idiopathic PD. This neurological disorder is therefore a
polygenic disease with various genetic and environmental contributors cumulatively directing its
pathological development.
Since the identification of the first missense substitution in SNCA (Polymeropoulos et al., 1997),
the gene encoding α-synuclein, the understanding of the genetic contribution to PD has progressed
rapidly and has become rather complex. In addition to the emergence of multiple loci as causative
factors in familial PD (Table 1), genome wide association studies (GWAS) and Genome-wide
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neurotransmitters (Burré et al., 2010; Garcia-Reitböck et al.,
2010; Bendor et al., 2013). The pathology of α-synuclein is largely
due to its propensity to aggregate; gradually transitioning from
small soluble oligomers to larger insoluble fibrils, ultimately
forming Lewy bodies. Although the majority of α-synuclein is
present in the cytosol, the protein also localizes to mitochondria
and induces dysfunction (Devi et al., 2008; Parihar et al.,
2008; Liu G. et al., 2009; Nakamura et al., 2011; Subramaniam
et al., 2014; Chen et al., 2015; Di Maio et al., 2016). Multiple
mitochondrial targeting domains have been identified within
the N-terminal domain of the protein and confer its ability to
bind to components of the mitochondrial membrane (Devi
et al., 2008). Specifically, α-synuclein can bind to cardiolipin
(Nakamura et al., 2008), TOM20 (Di Maio et al., 2016), TOM40
(Devi et al., 2008) and VDAC (Rostovtseva et al., 2015) either
to directly promote dysfunction at the membrane level or to
allow import into other mitochondrial compartments. The
importance of the N-terminal domain in mitochondrial targeting
is emphasized by the fact that α-synuclein-A53T, a mutant with
a substitution in the N-terminal region, has a greater binding
affinity for mitochondria than the wild type protein (Devi
et al., 2008). However, more recently it has also been argued
that, rather than localizing to the mitochondria, α-synuclein
specifically targets the mitochondria-associated endoplasmic
reticulum membrane (MAM) where it plays a role in regulating
mitochondrial morphology (Guardia-Laguarta et al., 2014).
Recent studies have demonstrated that α-synuclein
induces mitochondrial dysfunction in vivo. Mice with global
overexpression of human wild type α-synuclein in the brain
using the Thy1 promoter exhibited age dependent accumulation
of α-synuclein in mitochondria of the nigrostriatal dopaminergic
pathway, impaired electron transport chain function and
enhanced oxidative stress (Subramaniam et al., 2014). Mice with
inducible α-synuclein-A53T exhibited severe mitochondrial
fragmentation that preceded dopaminergic neurodegeneration
and other pathologies (Chen et al., 2015). These detrimental
effects may be caused by the direct and specific binding between
α-synuclein and outer mitochondrial membrane components
such as TOM20 and VDAC (Rostovtseva et al., 2015; Di
Maio et al., 2016). Di Maio et al. (2016) demonstrated that
oligomeric, dopamine-modified and phosphorylated species
of α-synuclein bound to TOM20 and prevented the import
of multiple mitochondrial proteins leading to mitochondrial
dysfunction. Similarly, binding of wild-type α-synuclein to
VDAC was sufficient to block the channel preventing bidirectional metabolite transfer thus promoting dysfunction
(Rostovtseva et al., 2015). In addition to blocking the channel,
α-synuclein was able to translocate through VDAC to gain
access to inner mitochondrial compartments, many of which
being direct pathological targets, including respiratory complex
components. A similar relationship has been reported for TOM40
as antibodies against this channel prevented the mitochondrial
import of α-synuclein (Devi et al., 2008). In addition to these
detrimental effects on mitochondrial function, α-synuclein also
interferes with normal mitochondrial dynamics (fission, fusion,
and transport). Overexpression of both wild type and mutated
forms of α-synuclein is associated with severe fragmentation

complex trait analysis (GCTA) have uncovered a significant
genetic component to the idiopathic disease (Hernandez et al.,
2016; Przedborski, 2017). Although mutations in these genes
alone may not be considered as causative, they significantly
increase the risk of developing idiopathic PD. This is, at
least in part, due to incomplete and variable penetrance of
the majority of these mutations. The emergence of genetic
risk factors for cases of idiopathic PD raises an important
question: What is causing the increased susceptibility to
the disease in individuals that carry these mutations? One
possible and particularly pertinent explanation is that risk
factor mutations render the individual more sensitive to the
pathological influence of environmental factors thus bringing
the idea of gene–environment interactions to the forefront.
This review will discuss the impact of genetic mutations,
environmental toxicants and gene–environment interactions on
PD pathogenesis. Furthermore, we will highlight mitochondria
as a common target for both genes and environmental toxicants
linked to PD.

GENETIC MUTATIONS IN PD
Autosomal-Dominant Genes
SNCA
Perhaps the most researched PD-linked gene to date is SNCA,
which encodes α-synuclein. While mutations in this gene are rare,
the SNCA locus is appreciated to be a significant variant factor
for PD development (Lill et al., 2012). The missense mutation
α-synuclein-A53T (Polymeropoulos et al., 1997) was the first
gene to be attributed to disease development and its discovery
represents a defining moment in PD research, not only preceding
the identification of many other genetic determinants of PD but
also mechanisms of sporadic disease. Since then, other point
mutations in α-synuclein (A30P, E46K, G51D, and H50Q), as
well as gene duplications and triplications, have been identified
in familial PD (Krüger et al., 1998; Singleton et al., 2003; Zarranz
et al., 2004; Appel-Cresswell et al., 2013; Lesage et al., 2013). The
fact that duplications and triplications of SNCA can also cause
PD (Singleton et al., 2003) is significant because it indicates that
elevated wild type α-synuclein alone is sufficient to cause disease.
So far, A53T has been found in seven families worldwide and only
one family for each other four missense mutations. Duplications
are more common than triplications, which has been found in
several families (Hernandez et al., 2016). α-synuclein is also
understood to be a key factor of sporadic PD and present in
Lewy bodies, which are abnormal proteins commonly observed in
PD (Spillantini et al., 1998). α-synuclein-associated mechanisms
have therefore been at the forefront of the PD research and
multiple high profile discoveries have greatly contributed to the
understanding of disease pathology. For example, as discussed
below, the discovery that α-synuclein pathology can spread from
one cell to another in a prion-like fashion has provided a key
insight into how PD may develop and provide novel therapeutic
strategies.
α-synuclein is a pre-synaptic protein that plays a
role in SNARE complex assembly and the exocytosis of
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TABLE 1 | Major monogenic mutations and associated risk genes in PD.
Gene

PARK Locus

Gene Locus

Inheritance

Mutations

Prevalence

First reference
linked to PD

Method of
identification

SNCA

PARK 1/4

4q21-22

AD

A53T, A30P, E46K,
G51D, H50Q,
duplications, triplications

Rare, A53T is most
frequent but only found
in seven families
worldwide

Polymeropoulos et al.,
1997; Krüger et al.,
1998; Singleton et al.,
2003; Zarranz et al.,
2004; Appel-Cresswell
et al., 2013; Lesage
et al., 2013

GW-Linkage

LRRK2

PARK 8

12q12

AD

>100 missense and
non-sense mutations
high risk variants, >15 of
which are pathogenic

Upto 40% of familial
and up to 10% of
sporadic cases

Funayama et al., 2002

GW-Linkage

VPS35

PARK 17

16q11.2

AD

D620N

1% of familial and 0.2%
of sporadic cases

Vilarino-Guell et al.,
2011; Zimprich et al.,
2011

Exome sequencing

CHCHD2

PARK 22

7q11.2

AD

10 mutations (see
Koschmidder et al., 2016)

Not available

Funayama et al.,
2015; Ogaki et al.,
2015

GW-Linkage

GBA

N/A

1q21

AD

>300 mutations, L444P
and N370S are most
common

Varies in different PD
populations but up to
31% in Ashkenazi
Jewish PD patients

Tsuji et al., 1987;
Neudorfer et al., 1996

Candidate gene

Parkin

PARK 2

1p35-36

AR

∼147 exonic mutations

77% familial EOPD and
10–20% EOPD in
general

Kitada et al., 1998

GW-Linkage

PINK1

PARK 6

6q25.2-27

AR

>60 mutations,

>9% EOPD

Valente et al., 2004a

GW-Linkage

DJ-1

PARK 7

1p36

AR

>10 mutations

1–2% EOPD

Bonifati et al., 2003

GW-Linkage

ATP13A2

PARK 9

1p36

AR

>10 mutations

Rare (found in 11
families)

Ramirez et al., 2006;
Di Fonzo et al., 2007

GW-Linkage

FBXO7

PARK 15

22q12-13

AR

R378G, R498X, T22M,
L34R

Rare

Shojaee et al., 2008

GW-Linkage

PLA2G6

PARK 14

22q13.1

AR

R741Q, R747W and
more

Rare

Paisan-Ruiz et al.,
2009

GW-Linkage

EOPD, Early-onset PD (Age at onset <50 years old); LOPD, Late-onset PD (Age at onset ≥ 50 years old); AD, Autosomal dominant; AR, Autosomal recessive;
GW, Genome-Wide.

glucocerebrosidase (GBA), have functions related to autophagy
and mitophagy, emphasizing the importance of this pathway
in the disease. Mitochondrial dysfunction may be able to
inhibit the autophagy pathway, perhaps by a reduction in ATP
availability and increased reactive oxygen species (ROS). Equally,
impaired autophagy can promote mitochondrial dysfunction by
the reduced clearance of damaged, dysfunctional organelles. The
complex relationship between these two cellular pathways is not
fully understood, particularly regarding the question of whether
mitochondrial dysfunction precedes impaired autophagy or vice
versa. Regardless, the interaction between these two fundamental
processes represents a critical area of future research in the
neurodegenerative field.
As mentioned above, α-synuclein has a direct interaction with
the autophagy pathway. Overexpression of wild type α-synuclein
was shown to directly modulate autophagy via inhibition
of Rab1a protein, which is important for autophagosome
formation (Winslow et al., 2010). Impaired autophagy has
been demonstrated in vivo using mice overexpressing wild-type
α-synuclein (Ebrahimi-Fakhari et al., 2011) or A53T α-synuclein
(Yu et al., 2009; Chen et al., 2015). Conversely, an impairment in

and reduced motility in vitro and in vivo through direct and
indirect mechanisms (Kamp et al., 2010; Nakamura et al., 2011;
Gui et al., 2012; Guardia-Laguarta et al., 2014; Chen et al., 2015;
Bido et al., 2017). Another negative impact of α-synuclein on
mitochondria is its ability to reduce mitochondrial biogenesis
(Zheng et al., 2010; Siddiqui et al., 2012). Following the onset of
oxidative stress, α-synuclein can bind to the promoter region of
Peroxisome proliferator-activated receptor gamma coactivator
1-alpha (PGC1α), a key component of mitochondrial biogenesis,
and inhibit the expression of downstream genes (Siddiqui et al.,
2012). Lastly, multiple α-synuclein species may also promote
the formation of dysfunctional mitochondria by increasing the
prevalence of mitochondrial DNA mutations (Martin et al., 2006;
Bendor et al., 2013).
In addition to these direct effects, α-synuclein can also
affect mitochondrial function through indirect mechanisms.
For example, it is increasingly evident that mitochondrial
function and autophagy are tightly linked. A reduced autophagic
capacity has been identified in many neurodegenerative diseases,
including PD. Many of the genes implicated in familial
PD, including SNCA, PINK1, Parkin, LRRK2, DJ-1 and
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of multiple mutations has led to LRRK2 being identified as a risk
factor for sporadic PD (Nalls et al., 2014; Hernandez et al., 2016).
Sporadic PD patient derived cells also display a slightly increased
basal activity of LRRK2, however, it is not known whether this
is causative or a consequence of pre-existing pathology (Esteves
et al., 2015). Interestingly, a recent study demonstrated that
variability within the DNM3 gene influences the age of onset in
G2019S carriers (Trinh et al., 2016). The presence of other genetic
modifiers may therefore influence disease manifestation in the
case of LRRK2 mutations.
The complex physiological roles of LRRK2 are not fully
understood; however, it is associated with many cellular
functions, particularly those involving membrane dynamics,
including autophagy, cytoskeletal dynamics, vesicle dynamics
and mitochondrial function. Attempts to better understand how
LRRK2 mutations contribute toward PD pathology have been
restricted partly due to the difficulty in creating a LRRK2
transgenic model that recapitulates important features of PD.
The majority of mutant LRRK2 transgenic models do not display
appreciable dopaminergic neurodegeneration, but do exhibit
multiple synaptic deficits including reduced vesicle endocytosis
(Arranz et al., 2015) and altered dopamine release, uptake and
signaling (Li et al., 2009; Tong et al., 2009; Melrose et al., 2010;
Walker et al., 2014; Beccano-Kelly et al., 2015; Yue et al., 2015).
LRRK2 has been shown to impair mitochondrial dynamics by
physically interacting with Drp1 and promoting mitochondrial
fragmentation associated with enhanced mitochondrial fission,
increased ROS generation and impaired autophagy (Niu et al.,
2012; Wang et al., 2012; Stafa et al., 2014; Esteves et al.,
2015). In addition to increased Drp1 expression, a concomitant
increase in Drp1-S616 phosphorylation has been reported.
This specific modification is a marker for increased Drp1
activity (Wang et al., 2012; Stafa et al., 2014; Esteves et al.,
2015). Overexpression of the gain of function mutations
G2019S and R1441C resulted in a reduction of mitochondrial
membrane potential, reduced complex IV activity, increased
uncoupling, altered mitochondrial motility, and an imbalance
in calcium signaling (Cooper et al., 2012; Papkovskaia et al.,
2012; Cherra et al., 2013; Godena et al., 2014). Ultrastructural
studies show an accumulation of condensed, disorganized and
damaged mitochondria consistent with deficits in mitophagy and
mitochondrial dynamics (Ramonet et al., 2011; Yue et al., 2015).
Finally, increased mtDNA mutations have been identified in
cerebrospinal fluid (CSF) and iPSCs derived from patients with
the G2019S mutation (Sanders et al., 2014; Podlesniy et al., 2016).
Taken together, although the mechanism is not entirely clear,
a toxic gain of kinase function in LRRK2 mutations negatively
affects mitochondrial function.
Mitochondrial dysfunction induced by LRRK2 also provides
a strong link to the impaired autophagy pathway in multiple
models. For example, an accumulation in autophagic and
lysosomal structures occur both in vitro and in vivo caused
by overexpression of PD-associated mutations (MacLeod et al.,
2006; Plowey et al., 2008; Gomez-Suaga et al., 2012). A block
in autophagy flux, increase in p62 levels and an accumulation
of autophagosomes have been demonstrated in dopaminergic
neurons generated from PD patient-derived induced pluripotent

autophagy pathways promotes the formation and accumulation
of higher order α-synuclein species, thus creating a cycle of
neurotoxicity (Xilouri et al., 2016). In summary, α-synuclein can
impair mitochondrial function at multiple levels: inhibition of the
electron transport chain, imbalanced mitochondrial dynamics,
reduced mitochondrial biogenesis and autophagy blockade.
Emerging evidence indicates that α-synuclein can spread
inter-cellularly through multiple mechanisms, including nonclassical exocytosis, exosomal release and nanotubes that directly
connect the two cells (Guo and Lee, 2014). According to the Braak
staging hypothesis (Hawkes et al., 2007), the olfactory bulb and
the gut are the initial spreading sites of misfolded α-synuclein.
Consistent with this hypothesis, accumulation of α-synuclein has
been identified in enteric neurons of patients with early-stage
PD (Hilton et al., 2014). Mitochondria have been implicated
in the pathological spread in neurons of both the enteric and
central nervous systems. For example, structural mitochondrial
abnormalities have been identified in enteric neurons of postmortem tissue from PD patients (Baumuratov et al., 2016). In
primary human fetal enteric neurons, exposure to recombinant
α-synuclein induces mitochondrial dysfunction involving a
reduction in complex I activity and impairment of mitochondrial
respiration (Braidy et al., 2014). Exposure of enteric neurons to
the environmental neurotoxin, rotenone, promotes the release
of α-synuclein species which are subsequently taken up by and
form aggregates in second-order neurons (Pan-Montojo et al.,
2012). Exposure of rat ventral midbrain neurons to exogenous,
pre-formed fibrillar structures of α-synuclein, often used to study
the transmission of the protein, also produce mitochondrial
dysfunction (Tapias et al., 2017). These studies, and others,
suggest that mitochondria may play a central role in the spread
of α-synuclein from one neuron to another. That said, however,
the topic of whether α-synuclein is transmitted trans-synaptically
in PD is still a topic of debate (Brundin and Melki, 2017; Surmeier
et al., 2017), which is beyond the scope of this article.

LRRK2
First identified in a family of Japanese origin (Funayama et al.,
2002) and subsequently independently confirmed in several other
families from different countries, leucine-rich repeat kinase 2
(LRRK2) mutations are the most common group of mutations
in PD cases (Cookson, 2015). Although highly dependent on
ethnicity, LRRK2 mutations are estimated to account for up to
40% of familial cases, depending on the ethnic background, and
up to 10% of sporadic PD cases worldwide (Hernandez et al.,
2016), producing a disease phenotype that is similar to that of
classical late-onset idiopathic PD. The most common and well
characterized LRRK2 mutation, G2019S, alone is suggested to
account for 4% of familial and 1% of sporadic cases. All described
LRRK2 mutations, to date, affect a central enzymatic region
of the protein consisting of a GTPase and kinase domain and
confer a gain of function (West et al., 2007). Although more
than 100 LRRK2 mutations have been reported, only a few such
as (N1437H, R1441C, R1441G, R1441H, Y1699C, G2019S, and
I2020T0) have been proven to cause PD and two have been
nominated as risk factors (R1628P and G2385R) (Dächsel and
Farrer, 2010; Paisan-Ruiz et al., 2013). The incomplete penetrance
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organization, with mitochondria appearing more rounded and
electron dense (Xu et al., 2014).
While the mechanisms of mitochondrial dysfunction
associated with GBA mutations are unclear, an impairment
of mitophagy is suggested to play an important role. This
is perhaps not surprising given the role of GBA in the cell
and this observation further strengthens the link between
autophagy and mitochondria. In mouse models and primary
fibroblasts, decreased mitophagy flux accompanied the observed
mitochondrial dysfunction (de la Mata et al., 2015). However,
whether an impaired mitophagy response causes the observed
mitochondrial dysfunction in these models or whether it is a
consequence of an upstream effect is not understood. Another
contributing factor to mitochondrial dysfunction in these
models is neuroinflammation. In GBA knockout mouse models,
activation of both astrocytes and microglia precedes disease
manifestation (Enquist et al., 2007; Farfel-Becker et al., 2011).
Astrogliosis has also been identified in some GD patients
that exhibit parkinsonian symptoms (Wong et al., 2004). It is
important to note that the majority of the studies related to GBA
discussed in this review have been performed in the setting of
GD rather than PD. Therefore, the conclusions made from this
work, although relevant, may not be directly transferrable to
cases of PD with GBA mutations.
GBA activity appears to be linked to the expression and
aggregation of α-synuclein. An accumulation of aggregated
α-synuclein, β-amyloid and amyloid precursor protein (APP) in
the cortex, hippocampus, striatum and substantia nigra of GBA
mutant mice was observed (Xu et al., 2014). Further, inhibiting
GBA, using zinc finger techniques, promotes the intercellular
transmission of α-synuclein species and therefore contributes
toward the spread of PD pathology (Bae et al., 2014). These
observations are consistent with the role of GBA in autophagy
function. An increase in α-synuclein expression has also been
shown to inhibit GBA activity (Mazzulli et al., 2011; Gegg et al.,
2012; Murphy et al., 2014), thus further impairing the clearance
of α-synuclein mediated by autophagy.

stem cells (iPSCs) expressing LRRK2-G2019S at endogenous
levels (Sánchez-Danés et al., 2012). Importantly, the inhibition of
mitochondrial fission, using the Drp1 peptide inhibitor P110, was
shown to improve autophagy and reduce detrimental changes
in cell morphology caused by the G2019S mutation in PD
patient fibroblasts and dopaminergic neurons derived from iPSCs
(Su and Qi, 2013). Conversely, another study showed that
disrupted mitochondrial motility and an increased vulnerability
to multiple stressors induced by G2019S and R1441C mutations
in PD patient iPSCs was rescued by the autophagy promoter
rapamycin (Cooper et al., 2012) Together, these studies suggest
that autophagy and mitochondrial function are bi-directionally
regulating one another.

GBA
An interest in GBA as a causative factor of PD followed
the clinical observations that some Gaucher’s disease patients
developed Parkinsonian symptoms (Neudorfer et al., 1996)
and that relatives of these patients had an increased risk of
developing PD (Halperin et al., 2006). Gaucher’s disease (GD,
Tsuji et al., 1987) is the most common lysosomal storage disorder
and is caused by homozygous and compound heterozygous
mutations in the GBA gene. GBA is a lysosomal hydrolase,
specifically a GBA which acts in the lysosomal membrane
to convert the sphingolipid glucosylceramide to glucose and
ceramide. Approximately 300 different mutations in GBA have
been identified with many shown to have reduced GBA activity.
Such reduction has indeed been identified in cases of PD with
GBA mutations but, importantly, it has also been identified in
the substantia nigra of sporadic PD brains (Gegg et al., 2012).
More severe mutations, such as L444P, increase the risk of
developing PD and promote an earlier onset as well as greater
cognitive decline when compared to milder mutations, such as
N370S. However, the overall mortality rate between these two
mutations is not significantly different (Gan-Or et al., 2015;
Arkadir et al., 2016; Cilia et al., 2016); therefore suggesting
that even a partial loss of function is sufficient to cause the
disease. The prevalence of GBA mutations varies in different
PD populations but is accountable for up to 31% of PD
patients with Ashkenazi Jewish ancestry (Sidransky and Lopez,
2012).
A reduction in GBA activity has been associated
with mitochondrial dysfunction. GBA inhibition, either
pharmacologically or genetically result in a reduction of
membrane potential and ATP production, as well as an increase
in oxidative stress and mitochondrial fragmentation in vitro
(Cleeter et al., 2013). These findings have been confirmed
using both fibroblasts isolated from GD patients and mouse
models of GD. Fibroblasts from GD patients, with an L444P
mutation, exhibited a reduction in complex I-III activity,
CoQ10 expression, membrane potential and ATP production
as well as an increase in oxidative stress (de la Mata et al.,
2015). Mouse models demonstrate a reduction in membrane
potential, complex I-III activity, oxygen consumption and an
increase in mitochondrial fragmentation in neurons and glia
(Osellame et al., 2013; Xu et al., 2014). Further, ultrastructural
analysis of mitochondrial morphology showed impaired cristae
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VPS35
A single mutation, D620N, in the gene encoding vacuolar protein
sorting 35 (VPS35) causes the development of an autosomal
dominant, late-onset PD (Vilarino-Guell et al., 2011; Zimprich
et al., 2011; Sharma et al., 2012). A number of other mutations
in the gene have been identified; however, their pathological
relevance is yet to be demonstrated. VPS35 mutations are rare
and only account for approximately 1% of familial and 0.2% of
sporadic PD cases.
VPS35 is a core subunit of a heteropentameric complex
known as the retromer, which plays an important role in
the transport of endosomes to the golgi apparatus and the
plasma membrane, as well as in recycling of transmembrane
protein cargo (Williams et al., 2017). In recent years VPS35
has also been reported to mediate the shuttling of cargo
from mitochondria to peroxisomes and lysosomes through
mitochondria-derived vesicles (Braschi et al., 2010; Sugiura et al.,
2014). Models of VPS35 mutations successfully demonstrate
dopaminergic neurodegeneration (Tsika et al., 2014; Wang et al.,
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variations spanning the entire length of the gene conferring a loss
of function (Klein and Westenberger, 2012). Parkin mutations are
considered as the most prevalent autosomal recessive mutations
in PD accounting for approximately up to 77% of familial
early-onset PD and 10–20% of early-onset PD in general (Klein
and Lohmann-Hedrich, 2007; Klein and Westenberger, 2012;
Kilarski et al., 2012). Mutations in PINK1, first identified in
an Italian family (Valente et al., 2001), are the second most
common cause of early-onset autosomal recessive PD accounting
for up to 9% of cases (Klein and Westenberger, 2012). Mutations
span the length of PINK1, with the majority being missense or
non-sense mutations and, similarly to Parkin, confer a loss of
function. Heterozygous PINK1 and Parkin mutations may also be
considered as a risk factor for developing PD (Khan et al., 2005;
Criscuolo et al., 2006; Hedrich et al., 2006; Hiller et al., 2007).
PINK1 is a Ser/Thr kinase that is localized to the mitochondria
(Hatano et al., 2004; Valente et al., 2004a,b; Zhou et al., 2008).
In a normal, healthy mitochondrion PINK1 binds to the outer
mitochondrial membrane (OMM), and is then imported into
the inner mitochondrial membrane (IMM) via the translocase
of the outer membrane (TOM) complex and translocase of
the inner membrane 23 (TIM23) in a membrane potentialdependent manner. Full length PINK1 is then rapidly cleaved
by mitochondrial processing peptidase (MPP) and presenilinassociated rhomboid-like protease (PARL). Cleaved PINK1 is
released into the cytosol for other non-mitochondrial functions
(Dagda et al., 2014) and can be degraded by the proteasome
(Meissner et al., 2011; Yamano and Youle, 2013). Hence, PINK1
is maintained at a low level in healthy mitochondria. However,
upon mitochondrial damage and the loss of membrane potential,
PINK1 import is blocked causing it to accumulate at the OMM
(Jin et al., 2010; Lazarou et al., 2012; Okatsu et al., 2013).
At the OMM, the kinase domain of PINK1 faces toward the
cytosol, enabling it to phosphorylate both mitochondrial and
cytosolic proteins (Zhou et al., 2008). Although not consistently
observed, PINK1 has been reported to phosphorylate ubiquitin
and ubiquitin-like (Ubl) domain of Parkin at a conserved
Ser65 residue. This phosphorylation initiates a cascade that
consequently activates and recruits Parkin, a ubiquitin E3 ligase,
to mitochondria (Durcan and Fon, 2015; Roberts et al., 2016).
Activated Parkin promotes ubiquitination of multiple OMM
proteins targeting them for degradation via the proteasomal
pathway (Gegg et al., 2010; Chan et al., 2011; Yoshii et al., 2011;
Kazlauskaite et al., 2014) as well as the recruitment of autophagy
adaptor proteins (Roberts et al., 2016). The PINK1/Parkin axis
is therefore an important pathway for mitochondrial quality
control and the selective removal of the damaged organelle by
mitophagy (Geisler et al., 2010; Narendra et al., 2010, 2012;
Vives-Bauza et al., 2010).
Mitochondrial abnormalities have been reported in multiple
in vivo and in vitro models of PINK1 and Parkin. PINK1 deficient
and PD-associated mutant models display reduced mitochondrial
membrane potential, ATP levels, reduced respiratory capacity
via complex I and IV activity, increased mitochondrial calcium
levels, sensitized mitochondrial permeability transition pore
opening and increased ROS production (Gautier et al., 2008,
2012; Piccoli et al., 2008; Dagda et al., 2009; Gandhi et al.,

2014, 2016; Tang et al., 2015). The pathogenic mechanism by
which VPS35 induces PD is not clear, however, recent studies
show that its mutation caused mitochondrial fragmentation,
impaired mitochondrial function, increased ROS, α-synuclein
accumulation and cell death (Tang et al., 2015; Wang et al.,
2016). The D260N mutant has an increased binding interaction
with Drp1, an effect that is further promoted by oxidative
stress, resulting in an increased turnover of mitochondrial Drp1
complexes via their mitochondria derived vesicular trafficking
to the lysosome for degradation (Wang et al., 2016). In
addition to increasing mitochondrial fission, VPS35 deficiency
or mutation induces mitochondrial fragmentation by impairing
mitochondrial fusion (Tang et al., 2015) via mitochondrial E3
ubiquitin ligase 1 (MUL1) upregulation, leading to increased
ubiquitination and proteasomal degradation of the fusion protein
MFN2. Together, these studies strongly support the role of VPS35
in imbalanced mitochondrial dynamics.

CHCHD2
Although little is known about the physiological roles of CoiledCoil-Helix-Coiled-Coil-Helix Domain Containing 2 (CHCHD2)
or its role in PD pathology, several mutations in the CHCHD2
gene cause an autosomal dominant form of late-onset PD and
dementia with Lewy bodies (Funayama et al., 2015; Ogaki
et al., 2015; Koschmidder et al., 2016). CHCHD2 contains a
mitochondrial targeting sequence in the N-terminal domain and
localizes to intermembrane space of mitochondria, where it binds
to the complex IV (cytochrome c oxidase, COX). This binding
is required for COX activity (Aras et al., 2015). CHCHD2 is
therefore necessary for oxidative phosphorylation (Baughman
et al., 2009). Indeed, reduced CHCHD2 expression results in
reduced COX activity, collapsed membrane potential and an
increase in ROS and mitochondrial fragmentation (Aras et al.,
2015), resulting in cell death in Drosophila (Meng et al., 2017).
PD-related mutant flies exhibited a chronic state of oxidative
stress, reduced oxygen consumption, ATP production, increased
cytochrome c release and displayed mitochondria with abnormal
ultrastructure leading to degeneration of dopaminergic neurons.
This study also suggests that CHCHD2 may be an important
mitochondrial stress response protein and can modulate cell
death signaling by interacting with cytochrome c and MICS1, a
member of the Bax inhibitor-1 superfamily (Meng et al., 2017).
Although CHCHD2 predominantly localizes in mitochondria
and directly binds to complex IV, CHCHD2 is also a transcription
factor of the complex IV subunit 4 isoform COX4I2 (Aras et al.,
2015). Because of this unique feature, loss of CHCHD2 function
negatively affects complex IV both functionally and structurally.

Autosomal-Recessive Genes
PINK1 and Parkin
Mutations in PTEN-induced kinase 1 (PINK1) and Parkin both
cause an almost identical form of autosomal recessive, early onset
familial PD which can present with or without Lewy Bodies
(Kitada et al., 1998; Sasaki et al., 2004; Valente et al., 2004a;
Samaranch et al., 2010). A mutation in Parkin was first identified
in a Japanese family (Matsumine et al., 1997; Kitada et al., 1998)
and are now collectively shown to encompass a wide range of
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enhanced vulnerability to the mitochondrial toxicant 1-methyl4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Kim et al., 2005;
Manning-Boğ et al., 2007).
DJ-1 is required for the proper balance of mitochondrial
dynamics; primary cortical neurons and embryonic fibroblasts
cultured from DJ-1 knockout mice and human dopaminergic
neuronal cells with DJ-1 knockdown exhibit mitochondrial
fragmentation and reduced Mfn2 levels (Irrcher et al.,
2010; Krebiehl et al., 2010; Thomas et al., 2011). Blocking
mitochondrial fission or promoting mitochondrial fusion
rescues this abnormal mitochondrial morphology (Irrcher et al.,
2010; Thomas et al., 2011). DJ-1 has also been suggested to
participate in the mitophagy pathway. In fact, loss of DJ-1 leads
to mitochondrial impairment and dysfunctional autophagy
(Irrcher et al., 2010; Krebiehl et al., 2010; Thomas et al., 2011)
and overexpression of PINK1 and Parkin is protective (Irrcher
et al., 2010; Thomas et al., 2011). These results are consistent
with the proposal that DJ-1 may be aiding PINK1/Parkin in
the clearance of misfolded proteins and damaged mitochondria
(Xiong et al., 2009; Thomas et al., 2011). Taken together, DJ-1
has a critical role in the oxidative stress response, mitochondrial
function and basal autophagy.

2009; Gegg et al., 2009; Liu W. et al., 2009; Morais et al.,
2009, 2014; Cui et al., 2010; Heeman et al., 2011). Isolated
mitochondria from brains of aged PINK1 null mice display
complex I deficits (Gautier et al., 2008; Morais et al., 2014)
and reduced calcium buffering capacity (Akundi et al., 2011).
Aged Parkin null brains show alterations in the expression of
a wide range of mitochondrial proteins, with many relating to
a reduced respiratory capacity and increased oxidative damage
(Palacino et al., 2004; Periquet et al., 2005; Stichel et al., 2007).
PINK1 and Parkin also play a regulatory role in mitochondrial
dynamics by mechanisms involving the turnover of fusion and
fission associated proteins such as Mfn1/2 and Drp1 (Clark et al.,
2006; Deng et al., 2008; Poole et al., 2008; Yang et al., 2008; Lutz
et al., 2009; Cui et al., 2010; Gegg et al., 2010; Tanaka et al., 2010;
Ziviani et al., 2010; Exner et al., 2012; Buhlman et al., 2014; Pryde
et al., 2016). However, whether PINK1 and Parkin are pro-fission
or pro-fusion has been a topic of debate (Exner et al., 2012; Pilsl
and Winklhofer, 2012).
In addition to the above effects on mitochondrial function
and dynamics, PINK1 and Parkin mediate biogenesis through an
indirect interaction with PGC-1α (Shin et al., 2011; Stevens et al.,
2015; Lee et al., 2017). The loss of PINK1/Parkin activity leads
to a reduced clearance, and consequent build-up, of the Parkin
Interacting Substrate (PARIS/ZNF746) which is a transcriptional
repressor of PGC-1α. An increase in PARIS/ZNF746 is identified
in the striatum and substantia nigra of patients with autosomal
recessive and sporadic PD, as well as in Parkin knockout mice
(Shin et al., 2011).

PLA2G6
Mutations in the PLA2G6 gene have been described in
patients with autosomal recessive early-onset dystoniaparkinsonism with widespread accumulation of Lewy
bodies and hyperphosphorylated tau (Paisan-Ruiz et al.,
2009; Miki et al., 2017). Brain iron accumulation is found
in most affected individuals (Paisan-Ruiz et al., 2009).
The PLA2G6 gene encodes a 85-kDa group VI calciumindependent phospholipase A2 β (PLA2G6) and is involved
in the hydrolysis of glycerophospholipids to release free fatty
acids and lysophospholipids (Ma and Turk, 2001). PLA2G6 is
confined to the mitochondrial compartment where it remodels
membrane phospholipids, protects mitochondria from oxidative
damage during apoptotic induction and takes part in calcium
signaling (Gadd et al., 2006; Seleznev et al., 2006; Strokin
et al., 2012). Although the pathological mechanism of PLA2G6
remains elusive, it has been suggested to affect lipid homeostasis
and metabolism as well as impact mitochondrial membranes
(Beck et al., 2011). Further, PLA2G6 knockout mice displayed
degenerated mitochondrial membranes and elevated levels
of synuclein (Sumi-Akamaru et al., 2016). PLA2G6 has been
reported to be immunopositive in the Lewy bodies of idiopathic
PD, suggesting its pathogenic role extends beyond familial PD
(Miki et al., 2017).

DJ-1
Homozygosity mapping in two consanguineous families from
Italy and the Netherlands with early-onset PD identified DJ-1
mutations (Bonifati et al., 2003). Collectively, mutations in DJ-1
account for approximately 1–2% of early onset recessive cases
of PD and encompass deletions, homozygous and heterozygous
point mutations and truncations (Bonifati et al., 2003). DJ-1 is
a small protein of 189 residues localized to the cytoplasm, the
nucleus and associated with mitochondria (Canet-Aviles et al.,
2004; Li et al., 2005; Junn et al., 2009). Among its functions, DJ-1
is involved in regulating mitochondrial activity (Hayashi et al.,
2009; Junn et al., 2009) and protecting against oxidative stress
(Taira et al., 2004).
DJ-1 can interact with mitochondrial complex I subunits
and is translocated to the mitochondria under stress conditions
(Hayashi et al., 2009). DJ-1 and its mutant forms could
associate with the chaperone protein Hsp70, a link that
was further increased under oxidative stress conditions.
These results suggest that translocation of DJ-1 to the
mitochondria may occur with the aid of mitochondrial
chaperone proteins (Li et al., 2005). It is believed that the
dimeric form of DJ-1 is required for antioxidative stress
reactions, while monomeric mutant forms of DJ-1 are toxic
for cells (Zhang et al., 2005; Maita et al., 2013). Further
studies also demonstrated mitochondrial dysfunction and
reduced membrane potential in DJ-1 knockout mice and flies
(Hao et al., 2010; Giaime et al., 2012). Consistent with its
protective role in mitochondria, DJ-1 knockout mice exhibit
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ATP13A2
ATP13A2 encodes ATPase type 13A, which is usually localized
to lysosomes. Mutations in ATP13A2 were initially identified
in Kufor–Rakeb syndrome (Ramirez et al., 2006), which is a
recessively inherited disease with multiple brain regions are
affected. Fibroblasts derived from these patients display reduced
ATP synthesis, increased mtDNA mutations, impaired oxygen
consumption and mitochondrial fragmentation (Grunewald
et al., 2012). Mutations in ATP13A2 are also found in early onset

7

November 2017 | Volume 8 | Article 177

Helley et al.

Mitochondrial Dysfunction in Parkinson’s Disease

that have been demonstrated to be toxic to the nigrostriatal
pathway.

parkinsonism (Di Fonzo et al., 2007), suggesting that ATP13A2
may also be relevant to PD. ATP13A2 is a multifunctional
protein that has been linked to endosome-lysosome dynamics
(Dehay et al., 2012; Usenovic et al., 2012), mitochondrial function
(Grunewald et al., 2012; Gusdon et al., 2012) and toxicity induced
by divalent cation metals (Mn2+ and Zn2+ ) (Gitler et al., 2009;
Kong et al., 2014). Consistent with these roles of ATP13A2, loss
of function in this protein has been reported to reduce the ability
of various vesicular structures such as lysosomes to regulate
divalent metal cations such as Mn2+ and therefore sensitize cells
to metal toxicity, accumulation of α-synuclein and mitochondrial
dysfunction (Gitler et al., 2009; Kong et al., 2014). These effects
are most likely secondary to autophagy deficits, causing an
accumulation of misfolded proteins and damaged mitochondria.
Collectively, ATP13A2 may exert an indirect, protective role on
mitochondria and the cell as a whole. Indeed, overexpression
of ATP13A2 is protective against α-synuclein-induced toxicity
(Gitler et al., 2009; Kong et al., 2014).

Pesticides
Rotenone
A potent non-competitive mitochondrial complex I inhibitor
derived from plants of the Leguminosa family (Soloway, 1976),
rotenone is a pesticide/piscicide associated with increased risk
of developing PD (Tanner et al., 2011; Kamel, 2013). Because
the half-life of rotenone is relatively short (∼3 days) (Hisata,
2002), consumption of contaminated food products is an unlikely
exposure route. The role of rotenone in PD is therefore most
likely through low chronic exposure rather than acute toxicity.
Epidemiological studies have demonstrated increased PD risk of
∼1.5–3-fold in individuals who utilized rotenone agriculturally
or who lived in close proximity to its use (Tanner et al.,
2011). As a highly lipophilic chemical, rotenone passes freely
through the blood-brain-barrier (BBB) and cellular membranes
and once inside cells it can directly alter mitochondrial
function. Rotenone impairs oxidative phosphorylation by
inhibiting NADH-ubiquinone reductive activity via binding
to the PSST subunit of complex I of the electron transport
chain (Schuler and Casida, 2001). This mechanism of rotenone
is relevant to the observations that mitochondrial complex
I activity is reduced in PD patients (Parker et al., 1989;
Schapira et al., 1989). Rotenone has also been shown to
enhance mitochondrial fission. In primary cortical neurons,
rotenone induces rapid mitochondrial fragmentation within
2 h of treatment, prior to any cellular changes indicative
of cytotoxicity (Barsoum et al., 2006). Altering mitochondrial
dynamics, by promoting mitochondrial fusion with Mfn2
and blocking Drp1 with Drp1-K38A averts this neurotoxicity
(Barsoum et al., 2006). Although the neuropathology is
variable, rotenone treatment has been shown to induce motor
impairment, neuroinflammation, nigrostriatal degeneration, and
accumulation and phosphorylation of α-synuclein (Betarbet
et al., 2000; Cannon et al., 2009) in rodent models of PD.
In addition to impairing mitochondrial function, rotenone
has been demonstrated to alter mitochondrial transport and
protein interactions within neurons. For example, rotenone
induces microtubule depolymerisation, thereby interfering with
the intracellular transport of vesicles and organelles, including
mitochondria (Choi et al., 2011). A recent study revealed
increased α-synuclein association with mitochondria, specifically
outer membrane protein TOM20, in nigrostriatal dopaminergic
neurons of rotenone-treated rats relative to controls (Di Maio
et al., 2016). This observation suggests that rotenone exposure
may induce α-synuclein-mediated changes in mitochondrial
function and morphology to further promote PD pathology.

FBXO7
Mutations within the FBXO7 (F-box only protein 7) gene have
been shown to promote either a typical PD phenotype (Lohmann
et al., 2015) or an early onset form of parkinsonian-pyramidal
syndrome (Shojaee et al., 2008; Di Fonzo et al., 2009). FBX07
has been linked to mitochondrial function by acting on the same
pathway as PINK1 and Parkin. It directly interacts with both
PINK1 and Parkin and therefore plays a role in mitochondrial
maintenance and mitophagy (Burchell et al., 2013; Zhou et al.,
2015). These studies demonstrate that FBXO7 assists in the
translocation of Parkin to the mitochondria in response to cell
stress and PD-associated mutations leading to a mislocalization
of FBXO7 to the cytosol where it can form toxic aggregates that
are deleterious to the cell (Zhou et al., 2015).

ENVIRONMENTAL EXPOSURES AS
POTENTIAL LINKS TO PD
Prior to the discovery of the first genetic mutation linked
to PD (Polymeropoulos et al., 1997) environmental factors
were the major focus of research aiming to understand PD
pathogenesis and etiology. The rationale for this dominant
environmental theory was largely based on observations
such as post-encephalitic infection, manganese (Mn) and
MPTP exposure causing parkinsonism (Rail et al., 1981;
Langston et al., 1983; Calne et al., 1994; Kwakye et al.,
2015). Multiple epidemiological studies and meta-analyses
have implicated a number of environmental factors, including
pesticides and heavy metals, with increasing PD risk (Tanner
et al., 2011; Wang et al., 2011; Kamel, 2013). These studies
support the proposition that chronic exposure to environmental
toxicants plays a major role in sporadic PD pathogenesis.
Pesticides and heavy metals are the most widely researched
environmental toxicants implicated in PD, and the ability of
some of them to persist in the environment long after their
application increases the likelihood of human exposure to these
contaminants. Following are some environmental exposures
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Paraquat
The herbicidal mechanism of paraquat (PQ) involves interference
with photosynthesis and oxygen free radical production, resulting
in damage of plant membranes (Tanner et al., 2011; Breckenridge
et al., 2013). Initially based on its similar structure to MPP+ ,
this widely used herbicide was hypothesized to be a potential
environmental parkinsonian toxicant (Snyder and D’Amato,
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1985). Epidemiological studies demonstrate that PQ exposure,
both alone and in conjunction with other pesticides, increases
the risk of developing PD (Costello et al., 2009; Ritz et al., 2009;
Tanner et al., 2011). To further understand the mechanism by
which this molecule induces dopaminergic neurotoxicity, PQ
has been used experimentally to model PD (Tieu, 2011). PQ is
unable to diffuse across the BBB and relies on transport by the
L-neutral amino acid transporter to enter the brain (Shimizu
et al., 2001; McCormack and Di Monte, 2003). Once inside
the brain, PQ can enter cells through the dopamine transporter
(DAT) and organic cation transporter-3 (Rappold et al., 2011). In
the cytosol, PQ induces toxicity primarily through redox cycling
with cellular diaphorases such as NADPH oxidase and nitric
oxide synthase (Day et al., 1999), leading to the generation of
superoxide. Despite its similar structure to MPP+ , PQ is not a
complex I inhibitor (Richardson et al., 2005), although this is
the site where superoxide is generated from PQ redox-cycling
in the mitochondria (Cochemé and Murphy, 2008). Other work
also implicates complex III in the formation of paraquat-induced
ROS (Castello et al., 2007). Consistent with the role of generating
mitochondrial ROS, a recent study reported mitochondrial DNA
damage in PD patients with prior history of exposure to PQ
(Sanders et al., 2017). The mechanism by which PQ enters
mitochondria, however, is currently unknown.
PQ has also been reported to increase mitochondrial
fission by reducing the levels of key mitochondrial fusion
factors, Mfn1/Mfn2 (Tanaka et al., 2010). In rodent models
PQ has been shown to cause neuroinflammation, as well
as α-synuclein upregulation and aggregation (Manning-Bog
et al., 2002; Wu et al., 2005; Fernagut et al., 2007; Purisai
et al., 2007). The use of PQ to model PD has been
contested by some, partly because studies utilizing wild-type
mice demonstrated variable results, with loss of dopaminergic
nigral cell bodies but a lack of consistency in the loss of
the corresponding striatal terminals (McCormack et al., 2002;
Thiruchelvam et al., 2003; Tieu, 2011); however, this lack
of striatal damage has been suggested to be the result of
compensatory sprouting from surviving dopaminergic neurons
and uptake of PQ into non-dopaminergic striatal cells. In
contrast to wild-type mice, mutant mice deficient in OCT3
(Slc22a3), a cation transporter which can uptake PQ into
cells, display enhanced striatal damage upon exposure to
PQ. This increased sensitivity likely results from reduced
buffering capacity by non-dopaminergic cells, leading to
increased availability of PQ to damage dopaminergic terminals
(Rappold et al., 2011). Despite the controversy which still
surrounds the use of PQ to model PD, current evidence from
epidemiological studies and mechanistic investigations appear
to sustain the conclusion that PQ may increase the risk of
developing PD.

which contributes to a persistent high risk of exposure, even
decades after its use has ceased. Human exposure risk may be
mediated through consumption of dairy products, meat, and
fish (Kanthasamy et al., 2005), although its high lipophilicity
also confers risk of dermal exposure, as it can be rapidly
absorbed through the skin. In addition to its environmental
persistence, the ability of dieldrin to bioaccumulate, with a
half-life of ∼300 days in humans, contributes to the risk it
confers, as it can readily pass the BBB and amass in the brain.
Indeed, dieldrin has been detected in 30% of post-mortem
brain tissue of PD patients, with none in age-matched control
brains (Fleming et al., 1994). Another study reported dieldrin in
both control and patient brain tissue, with significantly higher
levels in the caudate nucleus of PD patients (Corrigan et al.,
1996). These results support a potential role of this pesticide in
promoting nigral cell death and PD progression (Kanthasamy
et al., 2005).
Dieldrin has been shown to exert multiple effects on
mitochondria, including increased ROS production (Chun et al.,
2001) and stimulation of mitochondria-mediated apoptosis
(Kitazawa et al., 2003; Kanthasamy et al., 2008). Dopaminergic
cells have increased sensitivity to dieldrin when compared
to other cell types as demonstrated in vitro (Sanchez-Ramos
et al., 1998; Kitazawa et al., 2001) and in vivo (Sharma et al.,
1976; Wagner and Greene, 1978; Heinz et al., 1980). Dieldrin
(and other pesticides) have also been shown to block the
function of mitochondrial aldehyde dehydrogenase (ALDH
class 2) (Fitzmaurice et al., 2013, 2014). ALDH2 metabolizes
toxic aldehydes including 3,4-dihydroxyphenylacetaldehyde
(DOPAL), which is a reactive neurotoxic metabolite of dopamine.
Exposure of individuals with genetic variation in ALDH2 to these
pesticides was associated with a two–sixfold increase in their risk
of developing PD (Fitzmaurice et al., 2014). ALDH2 inhibition
therefore has been suggested as a pathogenic mechanism in
PD. Furthermore, based on a recent work that investigated
the proteomic effects of dieldrin, 18 proteins involved in the
respiratory chain were affected by dieldrin treatment (Cowie
et al., 2017), further supporting the influence of this pesticide on
mitochondrial function.
Dieldrin has also been demonstrated to directly stimulate
α-synuclein fibril formation in vitro, by inducing a
conformational change which may serve as a precursor or
seed for the aggregation of further protein (Uversky et al.,
2001b). Prolonged dieldrin exposure has been reported to
inhibit the ubiquitin-proteasome protein degradation system
(Sun et al., 2004), further promoting protein aggregation. In
summary, although the mechanistic understanding remains
incomplete, dieldrin has been shown to induce dopaminergic
neurotoxicity through mitochondrial dysfunction, decreased
protein degradation and apoptosis initiation.

Organochlorines

Pyrethroids

Dieldrin is one of the organochlorine pesticides that was
first commercially available in 1950, with wide use in the
United States until the late 1980’s. Despite decades of research
into potential risk of dieldrin, it is still extensively used in many
developing countries. Dieldrin has a long half-life (∼25 years)

Pyrethroids are synthetic derivatives of the naturally occurring
pyrethrum from chrysanthemum flowers. These pesticides are
widely used both agriculturally and in the household (Elwan et al.,
2006), however, despite their classification as safe substances
(Casida et al., 1983), pyrethroid intoxication in humans has
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their analogous redox behavior (Claus Henn et al., 2011; Kim
et al., 2013; Kwakye et al., 2015). Mn is essential for many
enzymatic reactions; it can act as a co-factor for glutamine
synthetase in astrocytes and it participates in the mitochondrial
antioxidant defence system as part of the superoxide dismutase
(MnSoD) (Borgstahl et al., 1992). Depending on its oxidative
state, Mn can be imported to the central nervous system
(CNS) through separate membrane importers such as the
divalent metal transporter 1 (DMT1) (highly expressed in
the basal ganglia), the DAT, calcium channels, choline and
citrate transporters, transferrin, and the ZIP (Zrt- and Irtrelated protein) family metal transporters (Huang et al., 2004;
Gunter et al., 2013; Tuschl et al., 2013). Metal efflux also
plays a critical role in maintaining the homeostatic levels of
Mn; although the number of proteins involved in exporting
Mn are limited compared to importer channels, they include
ferroportin (Fpn), SLC30A10 (solute carrier family 30 member
10), secretory pathway Ca2+ -ATPase 1 (SPCA1) and ATP13A2
(Tuschl et al., 2013). Chronic exposure to Mn can trigger
harmful effects in the brain clinically resulting in Manganism
(Couper, 1837), which is characterized by motor impairments,
behavioral changes and cognitive alterations. This movement
disorder has symptoms that resemble (Aschner et al., 2009),
but are distinct to, those of PD (Calne et al., 1994; Guilarte
and Gonzales, 2015). However, Mn exposure is believed to
contribute to increased PD risk in conjunction with other factors,
such as genetic susceptibility. In addition to environmental
exposure, mutations in the SLC30A10 gene (the first human Mn
transporter identified) cause an accumulation of Mn in both
the basal ganglia and the liver, inducing hypermanganesemia,
childhood onset dystonia and adult onset parkinsonism (Quadri
et al., 2012; Tuschl et al., 2012). Furthermore, in 2016, a
novel autosomal recessive Mn transporter defect (SLC39A14)
was discovered in children affected by hypermanganesemia
and progressive parkinsonism–dystonia. SLC39A14 represents a
specific Mn transporter as mutations in this gene impair Mn
uptake, without affecting any other metal levels (Tuschl et al.,
2016).
Although parkinsonism induced by Mn and PD share some
similar features, it is important to note that they are two
distinctive disorders (Calne et al., 1994; Guilarte and Gonzales,
2015; Kwakye et al., 2015). In fact, Mn-induced-parkinsonism
does not respond to levodopa, the most commonly used and
effective drug in PD. Moreover, it is believed that Mn primarily
affects gamma aminobutyric acid (GABA) producing neurons
in the globus pallidus while the numbers of dopaminergic
neurons in the substantia nigra remain relatively unaffected;
stereological cell quantification needs to be performed to
confirm these results (Guilarte et al., 2006; Guilarte and
Gonzales, 2015). Moreover, Guilarte et al. (2008) used Positron
Emission Tomography (PET) to show that Mn-exposed animals
exhibited reduced dopamine release in the dorsal striatum,
demonstrating an impaired nigrostriatal dopaminergic system
in Mn-exposed monkeys. Although Mn-induced parkinsonism
cannot be considered as idiopathic PD, Mn can still affect PD
pathogenesis by interacting with an individual’s genetic makeup
as discussed below, and epidemiological study has established

been observed (Chen et al., 1991). These chemicals, which
include permethrin and deltamethrin, readily cross the BBB and
may accumulate at considerable concentrations within the brain
(Anadón et al., 1996). Permethrin and deltamethrine have been
shown to increase DAT-mediated dopamine uptake by up to 30%
in the mouse striatum and induce apoptosis in dopaminergic
neuroblastoma cells (Elwan et al., 2006). Because the DAT
mediates neurotoxicity of some neurotoxicants (Gainetdinov
et al., 1997; Donovan et al., 1999; Rappold et al., 2011),
pyrethroids may enhance the vulnerability of dopaminergic
neurons to toxic compounds. Furthermore, permethrin has been
shown to potently inhibit mitochondrial complex I function
in rat liver (Gassner et al., 1997), however, a subsequent
study demonstrated that apoptosis induced by pyrethroids
(Deltamethrin) is mitochondrial independent (Hossain and
Weiner, 1993). Rather, deltamethrin induces calcium overload
through Na+ channels, leading to endoplasmic reticulum stress.
A recent study investigated the potential use of permethrin
to model PD in a progressive model of early life exposure
to the pesticide (Nasuti et al., 2017). Treatment of Wistar
rat pups with permethrin from post-natal days (PND) 6–
21 induced cognitive impairments, reduced striatal dopamine
levels and reduced dopaminergic neurons in the substantia
nigra; all common neuropathological changes detected in
PD patients. These changes were first obvious at PND 60,
although no motor changes were recorded until testing at
PND 150. This study adds a new potential pesticide model
of PD to the repertoire currently utilized for research, and
highlights an important consideration as early life exposure
to some toxicants may pre-dispose individuals to pathogenic
changes later in life, or initiate slow progressive changes
which culminate in development of the clinical phenotype.
Despite the demonstration of the neurotoxicity of pyrethroids
in experimental models, there appears to be insufficient
human data to link pyrethroids exposure to PD (Costa,
2015).

Heavy Metals
Copper, iron, zinc, and Mn represent some of the heavy metals
involved in the development of neurodegeneration. Collectively,
these metals are required for many physiological activities,
however, excessive levels may detrimentally affect cell viability
through mechanisms such as mitochondrial dysfunction and
oxidative stress (Martinez-Finley et al., 2013; Park et al., 2015).
They can also promote DNA damage and interact with proteins
that are directly involved in neurotoxicity, such as α-synuclein
and β-amyloid, by altering their structures (Cervantes-Cervantes
et al., 2005; Ha et al., 2007; Salvador et al., 2010; Chen et al., 2016).
Taken together, these effects will eventually disrupt a variety
of cellular processes and lead to increased risk of neurological
damage.
Of the heavy metals implicated in PD, Mn has received
the most attention. Mn is an essential metal characterized by
its vital role in brain development and homeostasis (Aschner
and Aschner, 2005). It has several chemical forms with 11
oxidation states and its metabolism is tightly linked to that
of other heavy metals, in particular that of iron due to
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that restoring mitochondrial health in either cell type is
neuroprotective.

an accumulation of Mn levels in PD patients (Fukushima
et al., 2010). In addition, chronic exposure to Mn results in
significantly increased Mn levels in dopaminergic neurons of
rodent brains compared to control animals (Robison et al., 2015).
Therefore, it is possible that Mn can enhance the susceptibility
of the individual to developing PD or accelerate the disease
onset.
The precise pathological mechanism of Mn toxicity is
not known, however, evidence suggests a direct interaction
with mitochondria and subsequent induction of mitochondrial
damage. Mn can enter mitochondria as Mn2+ through the
Ca2+ uniporter channel and slow export occurs via the Na+ independent Ca2+ channel (Gavin et al., 1999). High Mn2+
concentrations can accumulate in the mitochondrial matrix
and promote Na+ -dependent and Na+ -independent Ca2+ efflux
channel through direct competitive inhibition. This subsequently
causes an increase of mitochondrial Ca2+ levels, which interfere
with oxidative respiration and induce oxidative stress (Gavin
et al., 1990). It has been suggested that ROS induction can
originate from superoxide which can then be converted in the
mitochondria to hydrogen peroxide by the Mn and Cu/Zn
superoxide dismutase. Hydrogen peroxide can be reduced to
form hydroxyl radicals in the presence of Mn or other transition
metals via the Fenton reaction (Goldstein et al., 1993; MartinezFinley et al., 2013). The ROS generated by excessive Mn levels
promote opening of the mitochondrial permeability transition
pore, causing a loss of membrane potential, impaired ATP
synthesis and mitochondrial swelling, contributing to cellular
apoptosis (Gavin et al., 1990; Gavin et al., 1992). Gunter
et al. (2010) measured ATP production to study how Mn2+
promotes inhibition of the complex oxidative phosphorylation
system in multiple organs (liver, heart, and brain mitochondria).
Their results showed that Mn2+ inhibits ATP production in
different manners when comparing the different tissues. It
appears that Mn2+ inhibits two independent sites in brain
mitochondria: the primary site is electron transport chain
complex II, while the second is either the glutamate/aspartate
exchanger or the aspartate aminotransferase (Gunter et al.,
2010).
Although previous studies have focused their attention
on the effects of Mn on mitochondria and its capacity to
interfere with oxidative phosphorylation, there is little evidence
of the involvement of mitochondrial dynamics following
Mn neurotoxicity. A recent study, however, showed that
Mn induced changes in mitochondrial-shaping proteins
(Opa-1, Mfn-2, and Drp-1) by shifting the balance toward
mitochondrial fission (Alaimo et al., 2014). Indeed, an increased
amount of Drp-1 translocation to the mitochondria was
observed, indicative of increased mitochondrial fission.
Mn-induced apoptosis was prevented when Drp-1 was
inhibited (Alaimo et al., 2014). Furthermore, Mn toxicity
could promote inflammatory events by directly modulating
mitochondrial dynamics in astrocytes, and addition of
mito-apocynin (a mitochondrial targeted antioxidant)
significantly reduced Mn-induced inflammation (Sarkar
et al., 2017). These studies demonstrate that Mn impairs
mitochondrial function in both glia and neurons and
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Dietary Exposures
Diets have been documented to have an impact on the risk of
developing PD. Strong epidemiological evidence indicates, for
example, that cigarette smoking and coffee drinking are inversely
correlated to PD development (Hernán et al., 2002). On the
other hand, certain dietary exposures have also been linked to
parkinsonism. Annonacin is one such example.
Annonacin is a chemical derived from plants of the Annonacae
family, such as the soursop fruit, which has been implicated in
the development of atypical parkinsonism in Guadeloupe. In the
1990’s it was observed that a high proportion of Guadeloupe’s
population exhibited levodopa-resistant parkinsonism, with
presentation of bradykinesia, rigidity, postural instability, and
in some cases dementia (Caparros-Lefebvre and Elbaz, 1999;
Caparros-Lefebvre et al., 2002). Annonacin belongs to the
acetogenins, a class of large, structurally homogenous polyketides
which act as potent mitochondrial poisons via inhibition of
mitochondrial complex I (Tormo et al., 1999; Motoyama et al.,
2002). Studies of annonacin have demonstrated its potency for
complex I inhibition to be up to 50 times greater than that of
MPP+ , and at least equal to that of rotenone, consistent with
its ability to cause drastic neuronal loss and the development
of parkinsonian symptoms in a similar manner to these
two PD-linked complex I inhibitors (Lannuzel et al., 2006).
Acetogenins are highly toxic and have been shown to cause
loss of dopaminergic neurons at nanomolar concentrations
in vitro (Lannuzel et al., 2006). Due to its lipophilic nature,
annonacin does not require specific transporters for entry into
the brain or cells and it inhibits complex I function in both
neuronal and glial populations (Degli Esposti, 1998; Lannuzel
et al., 2006). Although the effects of annonacins are not
specific to dopaminergic neurons, neurodegeneration of the basal
ganglia is the most pronounced, with reduced alteration of the
hippocampus, cerebellum and cerebral cortex (Lannuzel et al.,
2006). Studies have confirmed that annonacin-treated rats exhibit
neurodegeneration characteristic of PD, with stereological cell
counts detailing significant loss of dopaminergic neurons in
the substantia nigra, reduced dopaminergic striatal terminals
and significantly increased astrocyte and microglial reactivity
(Champy et al., 2004; Lannuzel et al., 2006).
Annonacin treatment of primary embryonic striatal neurons
induces retrograde mitochondrial transport, with some
mitochondria displaying tau protein association with their
outer membranes, suggesting that annonacin may also confer
risk for other neurodegenerative disorders, including Alzheimer’s
disease (Escobar-Khondiker et al., 2007). The authors surmised
that ATP-depletion induces this mitochondrial withdrawal from
cellular extremities, which may in turn mediate loss of these
axonal terminals due to insufficient fulfillment of their energy
demands (Escobar-Khondiker et al., 2007). In humans with
chronic exposure from fruit consumption, synergistic effects of
annonacin with other acetogenins and alkaloids, which are also
present in some annonacin-containing plants, may contribute
to the putative toxicity of these fruits and the development of
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or organisms to scavenge ROS likely increase their susceptibility
to PQ neurotoxicity.
Attention has also been given to the interactions between
Mn and PD-linked gene products including α-synuclein, Parkin,
PINK1, DJ-1, LRRK2, ATP13A2, and VPS35, as recently
discussed in these reviews (Covy and Giasson, 2011; Roth, 2014,
Peres et al., 2016). Regarding its interaction with α-synuclein,
Mn can bind to this protein via three residues in the C-terminal
domain: Asp-121, Asn-122, and Glu-123 (Uversky et al., 2001a),
although biophysical studies showed that Mn exhibits a low
affinity for α-synuclein (1 mM range) compared to other
metals (Binolfi et al., 2006). X-ray fluorescence imaging also
indicates an interaction between α-synuclein and Mn in rat
primary midbrain neurons (Dućič et al., 2015). This study
reported that intracellular content of Mn was higher in cells
with α-synuclein overexpression, suggesting that α-synuclein
acts as an intracellular storage of Mn (Dućič et al., 2015).
Perhaps partly because of this property of α-synuclein, its
effects on cell viability has been reported to be both neurotoxic
and neuroprotective when combined with Mn. As extensively
discussed (Peres et al., 2016), although Mn has been reported
by several laboratories to enhance α-synuclein aggregation and
neurotoxicity when combined with α-synuclein, some studies
also showed that wild type α-synuclein is protective against Mn
neurotoxicity in Caenorhabditis elegans (Bornhorst et al., 2014)
and rat dopaminergic neuronal cells (Harischandra et al., 2015).
For the later study, protection was only observed during the
early stages of Mn exposure, suggesting that accumulation of
sequestered Mn would eventually induce protein aggregation and
neurotoxicity.
Most of the current evidence on ATP13A2 function comes
from studies focusing on the interaction between this protein
and α-synuclein. Given its role in lysosomal degradation it
is not surprising that mutations in this gene can lead to
diminished lysosomal-mediated clearance of autophagosomes
and accumulation of aggregated α-synuclein (Gitler et al., 2009;
Usenovic and Krainc, 2012). On the other hand, ATP13A2
has been shown to protect cells against Mn toxicity (Gitler
et al., 2009), however, this protection is lost when mutations
in this gene occur. A recent study showed that ATP13A2
mutations could increase the detrimental effects of Mn on motor
coordination in humans exposed to the heavy metal (Rentschler
et al., 2012).
Mn-exposed animals displayed mitochondrial impairment
and loss of tyrosine hydroxylase, a phenotypic marker for
dopaminergic neurons (Sriram et al., 2010). The expression of
Parkin and DJ-1 were also affected in these cells. Relevant to
Mn neurotoxicity, Parkin has been reported to regulate Mn
transport (Roth et al., 2010). The DMT1 transporter represents
the primary route for Mn uptake in the brain and four isoforms
have been identified. Parkin is involved in the ubiquitination and
subsequent proteosomal degradation of one of these isoforms
(Roth et al., 2010). Therefore, a loss of Parkin function could
facilitate Mn transport, promoting Mn accumulation in the basal
ganglia and accelerating its toxicity. DJ-1 and Mn have further
been implicated in mitochondrial dysfunction. Lee et al. (2012)
showed that Mn could reduce both protein and RNA levels of

neurodegenerative diseases (Lannuzel et al., 2003; Potts et al.,
2012).

Gene–Environment Interactions in
Parkinson’s Disease
As comprehension of the role of genetics and environmental
exposures in the development of PD increases, it has also become
clear that independently these factors cannot account for all
cases of sporadic PD. For example, it has been a topic of
great interest and debate why a single heterozygous mutation
in the recessive PINK1 and Parkin genes would lead to PD
in some patients (Klein et al., 2007). It is possible that these
heterozygous mutations increase susceptibility to environmental
toxicants. Equally interesting is the observation that mutations
in LRRK2 have also been detected in sporadic PD (Gilks
et al., 2005). Additional familial PD genes have also been
found among the risk loci identified for sporadic PD (Nalls
et al., 2014). The view of gene–environment interactions that
culminate in PD has increasingly been appreciated. However, the
specifics of such interactions have not been well documented.
Although some recent epidemiological studies have identified
a number of specific interactions that might be relevant
to PD (Cannon and Greenamyre, 2013), most results are
derived from genetically modified experimental models to
evaluate the sensitivity of neurons to toxicants as described
below.
Rotenone has been shown to interact with or to increase PD
risk due to association with multiple genes, including Parkin
and VPS-35. When primary neuronal cultures from wild type
or Parkin-knockout mice were treated with different rotenone
concentrations; the Parkin-knockout cultures were much more
sensitive to rotenone toxicity (Casarejos et al., 2006). Because
Parkin also functions in the mitophagy pathway, the cumulative
effects of Parkin defective cells with rotenone may relate to
the reduced clearance of defective mitochondria. Rotenone
exposure may therefore increase the likelihood of disease onset
in individuals with Parkin mutations, or it may decrease the
age of disease onset by potentiating the pathogenic process.
Increased vulnerability of primary neuronal cultures to rotenone
and VPS35 mutations have also been reported (Tsika et al., 2014),
suggesting that increased PD susceptibility due to combinatory
effects between rotenone and genetic modifications is not limited
to just a single gene.
Paraquat (PQ) also has a number of genetic modifications
linked to increased risk and PD susceptibility, including
CHCHD2 and PINK1 (Gegg et al., 2009; Meng et al., 2017).
Viability of PINK1−/− cells is reduced following treatment with
PQ compared to control cells (Gegg et al., 2009). This enhanced
vulnerability is likely due to the combination of reduced ATP
production and increased intracellular oxidative stress. Increased
mitochondrial dysfunction and susceptibility to apoptosis or
oxidative stress over time has also been reported in brain cells
with loss of PINK1 activity (Gautier et al., 2008; Wood-Kaczmar
et al., 2008). CHCHD2 is also shown to increase the sensitivity
of Drosophila to PQ-induced oxidative stress (Meng et al., 2017),
suggesting that genetic mutations which reduce the ability of cells
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first PD linked mutation was discovered in 1997, the search for
the cause of PD was primarily focused on environmental factors.
This approach seems logical given the absence of genetic evidence
at the time and the observations that PD/parkinsonism could be
caused by post-encephalitic infection and exposure to pesticides,
Mn, MPTP and diets as discussed in this review. However,
after the first discovery PD-linked mutation, PD research has
progressed at a rapid pace with exciting directions. In the last
few decades, we have learned tremendously about this disease.
However, the more we know, the more we realize how complex
this disorder truly is. To date, no other neurodegenerative
disorders exhibit so many genetic mutations (and yet they
represent only a small fraction of all cases), and with such a strong
environmental component as PD. The etiology of PD is complex
and multi-factorial.
What have we learned so far about PD etiology and
pathogenesis? We have identified several autosomal dominant
and recessive genes linked to familial PD, as well as those that

DJ-1 inducing an effect that resembled the neurotoxic activity of
mutant forms of DJ-1. Furthermore, the ability of both factors
to individually promote oxidative stress, increase opening of the
mitochondrial permeability transition pore, decrease membrane
potential and impair ATP represent possible exacerbating effects
of Mn and DJ-1 on mitochondrial activity. In summary, Mn
has been demonstrated to interact with many PD-linked gene
products and dysregulation of Mn homeostasis or exposure to
Mn may contribute to PD pathogenesis.

CONCLUSION AND FUTURE
DIRECTIONS
First described in 1817, PD is now recognized as a major
debilitating neurological disorder. To develop effective disease
modifying therapies or a cure, it is critical to understand what
causes PD and its associated pathogenic mechanism(s). Until the

FIGURE 1 | Common pathogenic mechanisms in Parkinson’s disease. (A) Mitochondrial dysfunction, a common pathogenic mechanism induced by many of the
environmental toxicants and genetic mutations linked to PD, results in a cascade of interconnected cellular dysfunction. (B) Neuroinflammation, facilitated by
microglia and to a lesser extent astrocytes, which release neurotoxic factors such as cytokines, interleukins and reactive oxygen species, leading to non-cell
autonomous neurotoxicity. (C) Increased mitochondrial fission and fragmentation, which can initiate apoptotic cell death by inducing cytochrome C release.
(D) Because autophagy and ubiquitin-proteasome system (UPS) are ATP-dependent processes, ATP reduction would reduces autophagic clearance of damaged
proteins and organelles. This process is also sensitive to reactive oxygen species (ROS). (E) Generation of ROS, which has the capacity to promote the formation of
toxic oligomers and protein aggregates (F), impair ubiquitin proteasomal system function (G), and induce DNA damage (both nuclear and mitochondrial DNA).
(H) Nuclear DNA encodes numerous mitochondrial proteins. DNA damage results in altered nuclear function, genomic instabilities, and mitochondrial dysfunction.
(I) Dysregulated cellular Ca2+ is influenced by mitochondrial dysfunction, because mitochondria help to regulate intracellular Ca2+ levels. When damaged,
mitochondria release more Ca2+ into the cytosol, thereby increasing cellular excitotoxicity. Over-activation of the excitatory receptors also results in excitotoxicity due
to Ca2+ influx which then produces downstream defects such as Ca2+ -induced mitochondrial depolarization. As illustrated, all these mechanisms cross-talk and
culminate in neurodegenerative processes in PD.
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FIGURE 2 | Interactions between gene products linked to PD. As discussed in the text, both genetic mutations and neurotoxicants linked to PD impair mitochondrial
function, whether directly or indirectly by interacting with each other. For the autosomal recessive gene products, PINK1 is accumulated at outer mitochondrial
membrane (OMM) of damaged mitochondria, where it recruits Parkin which ubiquitinates proteins and target them for degradation. Together, PINK1 and Parkin play
an important role in maintaining mitochondrial quality through mitophagy. As an antioxidant protein, DJ-1 is translocated to dysfunctional mitochondria when ROS is
generated. DJ-1 also aids PINK1 and Parkin in removing damaged mitochondria. Additionally, FBX07 is involved in the recruitment of Parkin to damaged
mitochondria and subsequent mitophagy. ATP13A2 is localized in lysosomes and is important for protein degradation. For the autosomal dominant gene products,
accumulation of misfolded and aggregated α-synuclein can be induced by a variety of neurotoxicants and genetic mutations. Toxic α-synuclein can impair
mitochondrial function, generate ROS and block autophagy/lysosomal function. Mutation in LRRK2 results in gain of toxic kinase function which impairs
mitochondrial and autophagic function as well as promotes α-synuclein aggregation. VPS35 mutations increase binding to Drp1 resulting in mitochondrial
fragmentation. Of note, mitochondrial fragmentation is a common observation induced by genes and toxicants linked to PD. CHCHD2 is rather unique because it is
both a mitochondrial protein and transcription factor. Its mutation impairs complex IV function and expression of a complex IV subunit. Mutations in GBA, a lysosomal
protein, impairs protein degradation and mitochondrial function. Although not shown for simplicity, neurotoxicants such as Mn also interact with these proteins (such
as α-synuclein) to induce neurotoxicity. Together, there are extensive interactions between these proteins and neurotoxicants leading to neurodegeneration.

mutations and environmental toxicants linked to PD, it
is evident that mitochondria are a common pathogenic
target (Figure 2). Given the extensive and critical role of
mitochondria, ranging from the classic “powerhouses” of the
cell, to maintaining calcium homeostasis, controlling synaptic
activity, initiating apoptosis and the spread of α-synuclein, it
is not surprising that impaired mitochondrial function would
negatively impact neuronal function and viability. The proposal
that mitochondria represent a common and convergent pathway
for PD raises some questions that might be worthwhile for future
research:
First, would therapeutically targeting mitochondria alone be
sufficiently efficacious? Given that other pathogenic mechanisms
(oxidative stress, neuroinflammation, protein aggregation, and
kinase activity) also occur in PD and that the mitochondrion
is not always the first neurotoxic target, perhaps a “cocktail”
therapy, a strategy used for HIV and cancer treatment,
is necessary. Second, regardless of whether mitochondrial

increase the risk of PD. The successive and rapid discoveries of
these genes have led many PD researchers to shift their focus to
genetic studies. However, we have now reached a stage where
we realize that even with additional genes to be discovered
in the future, genetics alone cannot account for all PD cases.
Data from epidemiological and genome-wide association studies
support the role of environmental factors and gene–environment
interactions in sporadic PD. Experimental models also reveal that
all three factors (genetic, environmental and gene–environment
interaction) have an impact on the nigrostriatal pathway. In
combination, these studies have provided significant insights
into mechanisms of neuronal dysfunction and degeneration
in PD. These non-mutually exclusive mechanisms include
mitochondrial dysfunction, oxidative stress, neuroinflammation,
toxic misfolded proteins, and insufficient protein degradation (as
illustrated in Figure 1).
In this review we focus our attention on the role of
mitochondrial dysfunction. By examining all the major genetic
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impairment is induced by environmental toxicants or genetic
mutations, multiple cell types in various brain regions would
be affected. Yet, dopaminergic neurons are the most vulnerable
cell type. Understanding what dictates this selective cell death
not only will shed light on disease pathogenesis but also
therapeutic strategy. It has been proposed that this process
involves a combination of selective expression of L-type Ca2+
channel leading to elevated cytosolic Ca2+ , oxidized cytosolic
dopamine, α-synuclein and the inherent long, highly branched
axons of nigral dopaminergic neurons (Obeso et al., 2017).
Although attractive, this hypothesis remains to be validated.
Third, in addition to mitochondrial dysfunction, another theme
gaining significant momentum is the autophagic impairment
pathway. Although limited, evidence exists to support that these
mechanisms, mitochondria and autophagy, are not mutually
exclusive and they can bi-directionally regulate each other. It is
not clear, however, which one would play a more prominent role.
Fourth, emerging evidence seems to support the idea of blocking
mitochondrial fission as a therapeutic strategy for PD and other
neurodegenerative disorders. However, because a balance of
mitochondrial fission/fusion is critical to normal physiological
process, how to target this pathway to achieve optimal therapeutic
with minimal side effects will require more efforts. In summary,
mitochondrial dysfunction is a pathogenic mechanism shared by

genetic mutations and environmental toxicants linked to PD.
However, substantial further research is required before a safe
and effective disease-modifying therapy may be translated into
the clinical setting.
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